We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Revance Therapeutics Inc | NASDAQ:RVNC | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.95 | -22.14% | 3.34 | 3.05 | 8.00 | 4.05 | 3.00 | 4.05 | 8,076,288 | 05:00:07 |
From May 2023 to May 2024
By Colin Kellaher
Shares of Revance Therapeutics rose more than 10% in premarket trading Monday after the U.S. Food and Drug Administration approved the expanded use of its Daxxify antiwrinkle treatment in its first therapeutic indication.
The Nashville biotechnology company on Monday said the FDA approved Daxxify for the treatment of adults with cervical dystonia, a painful condition in which the neck muscles contract involuntarily.
Revance last year won FDA approval of Daxxify for the temporary improvement of frown lines in adults, launching a competitor to AbbVie's Botox antiwrinkle injection.
Revance said the approval of Daxxify for cervical dystonia gives the company entry into the $2.5 billion U.S. therapeutic neuromodulator market.
Revance shares, which closed Friday at $18.91, were recently up 11% to $21 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 14, 2023 08:54 ET (12:54 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Revance Therapeutics Chart |
1 Month Revance Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
